Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Aim. To evaluate the effecacy of enalapril (Enam, Dr.Reddy’s, India) and atenolol (Tenormin, AstraZeneca, UK) and their influence on processes of cardiovascular system remodeling in comparative research in patients with arterial hypertension. Material and methods. 38 patients with arterial hypertension stage II were examined. 21 patients were treated with enalapril (10-40 mg\d) and 17 – with atenolol (50-100 mg\d). Duration of therapy was 24 weeks.  A daily monitoring of blood pressure and echocardiography were made before and after the treatment. Spontaneous erythrocyte aggregation and deformability, spontaneous platelet aggregation and adhesive property of neutrophils were also estimated. A number of leucocytes carrying activation markers and expressing adhesive molecules was calculated. The plasma concentration of adhesive molecules (ICAM-1) and von Willebrand protein as well as serum concentration of N-terminal peptide of procollagen type III was also estimated. Results. Enalapril versus atenolol improved blood rheology, reduced functional leucocytes activity, plasma concentration of von Willebrand protein and intercellular adhesive molecules. The reduction in collagen III synthesis activity in enalapril therapy was proved. A significant regress of left ventricle hypertrophy due to enalapril treatment was related with favorable non-hemodynamic effects. Conclusion. The research revealed that the blockage of tissue rennin-angiotensin system is very important in prevention of cardiovascular complications especially in high risk patients.

About the Authors

O. M. Moiseeva
Research institute of cardiology after V.A. Almazov, Roszdrav
Russian Federation

S. V. Villevalde
Research institute of cardiology after V.A. Almazov, Roszdrav
Russian Federation

I. V. Emelyanov
Research institute of cardiology after V.A. Almazov, Roszdrav
Russian Federation

T. G. Ivanova
Research institute of cardiology after V.A. Almazov, Roszdrav
Russian Federation


1. Moser M., Hebert P.R. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996; 27: 1214-1218.

2. Blood Pressure Lowering Treatment Trialists` Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362:1527-1545.

3. Национальные рекомендации по профилактике, диагностике и лечению артериальной гипертонии. Рекомендации экспертов Всероссийского общества кардиологов (ВНОК), вторая редакция. 2004.

4. Schillaci G,, Verdecchia P., Porcellati C. et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35: 580-586.

5. Pasternak R.C., Criqui M.H., Benjamin E.J. et al. Atherosclerotic vascular disease conference. Writing group I: Epidemiology. Circulation 2004; 109: 2605-2612.

6. Madhavan S., Ooi W.L., Cohen H., Alderman M.H. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395 - 401.

7. Blacher J., Pannier B., Guerin A.P. et al. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998; 32: 570 - 574.

8. Levy D., Garrison R.J., Savage D.D. et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.

9. Bots M.L., Hoes A.W., Koudstaal P.J. et al. Common carotid intimamedia thickness and the risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 1997; 96: 1432–1437.

10. Gasowski J., Fagard R.H., Staessen J.A. et al. Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups. J. Hypertens. 2002; 20:145-151.

11. Perticone F., Ceravolo R., Pujia A. et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-196.

12. Sciacqua A., Scozzafava A., Pujia A. et al. Interaction between vascular dysfunction and cardiac mass increases the risk of cardiovascular outcomes in essential hypertension. Eur. Heart J. 2005; 26; 921- 927.

13. Mancini G.B.J., Dahlоf B., Diez J. Surrogate Markers for Cardiovascular Disease. Structural markers. Circulation. 2004; 109: IV-22 – IV-30.

14. Devereux R.B., Reinchek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-618.

15. Hammond I.W., Devereux R.B., Alderman M.H. et al. Prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 1986; 7: 639 - 650.

16. Agewall S., Doughty R.N., Bagg W. et al. Comparison of ultrasound assessment of flow-mediated dilatation radial and brachial artery with upper and forearm cuff positions. Clin. Physiol. 2001; 21: 9-14.

17. Ашкинази И.Я. Эритроцит и внутреннее тромбопластинобразование. Л: Наука; 1977.

18. Моисеева О.М., Моисеев С.И., Гуревич В.С. Способ определения деформабельности эритроцитов. Лаб. Дело 1990; 10: 55-57.

19. Wu K.K., Hoak J.C. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet1974; 2: 924-926.

20. Ley K., Lundgren E., Berger E., Arfors K.-E. Shear-dependent inhibition of granulocyte adhesion to cultured endothelium by dextran sulfate. Blood 1989; 73: 1324-1330.

21. Suda K., Rothen-Rutishauser B., Gunthert M., Wunderli-Allenspach H. Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: endothelial versus epithelial features. In vitro cell dev boil anim. 2001; 37: 505-514.

22. Schmeider R.E., Martus., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507–1513.

23. Dahlof B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients – A metanalysis of 109 treatment studies. Amer. J Hypertens. 1992; 5: 95–110.

24. Schwartzkopff B., Strauer B.E. Coronary reserve in hypertrophy. In: Left ventricular hypertrophy, ed.: Sheridan D.J., Churchill living-stone, 1998: 127- 134.

25. Intengan H.D., Schiffrin E.L. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38: 581-587.

26. Landmesser U., Drexler H. Oxidative stress, the renin-angiotensin system, and atherosclerosis. Eur Heart J 2003; 5: A3-A7.

27. Lonn E.M., Yusuf S., Dzavik V. et al. Effects of ramipril and vitamin E on atherosclerosis.The study to evaluate carotid ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-925.

28. Zanchetti A., Crepaldi G., Gene Bond M. et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Stroke 2004; 35: 2807- 2812.

29. Teo K.K., Burton J.R., Buller C.E. et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis.The simvastatin/enalapril coronary athero- sclerosis trial (SCAT). Circulation 2000;102: 1748-1754.

30. HOPE Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.

31. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.

32. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115 – 126.

33. Шляхто Е.В., Моисеева О.М., Лясникова О.М., Виллевальде О.М., Емельянов И.В.Реологические свойства крови и функция эндотелия у больных гипертонической болезнью. Кардиология 2004; 44 (4): 20-23.

34. Шляхто Е. В., Конради А. О., Моисеева О. М. Молекулярно-генетические и клеточные аспекты ремоделирования сердца и сосудов при гипертонической болезни. Тер Архив 2004; 6: 51-58.

35. Фрейдлин И.С., Тотолян А.А. Клетки иммунной системы.- СПб.: Наука, 2000; I-II: 231.

36. Lip G.Y., Blann A. Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997; 34: 255 –265.

37. Becker B.F., Heindl B., Kupatt C., Zahler S. Endothelial function and hemostasis. Z Kardiol 2000; 89: 160 – 167.

38. Lip G.Y.H. Target organ damage and the prothrombotic state in hypertension. Hypertension 2000;36: 975- 977.

39. DeSouza C.A., Dengel D.R., Macko R.F et al. Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 1997; 10: 1335 – 1341.

40. Blann A.D., Nadar S., Lip G.Y. Pharmacological modulation of platelet function in hypertension. Hypertension 2003; 42: 1-7.

41. Verdecchia P ., Carini G., Circo A. et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 2001; 38: 1829-1835.

For citation:

Moiseeva O.M., Villevalde S.V., Emelyanov I.V., Ivanova T.G. COMPARATIVE RESEARCH OF ENALAPRIL AND ATENOLOL ANTIHYPERTENSIVE EFFICACY IN HIGH RISK PATIENTS. Rational Pharmacotherapy in Cardiology. 2006;2(3):19-25. (In Russ.)

Views: 517

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)